Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16903456 | 0.91 | GAA (0.54) | GAANR3C1SIGMAR1MC4RMEN1 | |
| SCHEMBL6580879 | 0.88 | CYP2D6 (0.47) | GAANR3C1SIGMAR1MEN1KMT2A | |
| SCHEMBL3140906 | 0.86 | KDM4E (0.46) | GAASIGMAR1POLBTACR1 | |
| SCHEMBL4364213 | 0.83 | GAA (0.53) | GAANR3C1SIGMAR1MC4RMEN1 | |
| SCHEMBL6581527 | 0.82 | GAA (0.51) | GAANR3C1SIGMAR1MEN1KMT2A | |
| SCHEMBL4369263 | 0.81 | GAA (0.50) | GAANR3C1SIGMAR1MC4RMEN1 | |
| SCHEMBL3315042 | 0.81 | NR3C1 (0.49) | GAANR3C1SIGMAR1MEN1KMT2A | |
| SCHEMBL13090069 | 0.81 | NR3C1 (0.52) | GAANR3C1SIGMAR1TSHRCYP2D6 | |
| Methane SCHEMBL726862 | 0.79 | NR3C1 (0.48) | GAANR3C1SIGMAR1MC4RMEN1 | |
| SCHEMBL29760370 | 0.78 | SIGMAR1 (0.55) | GAASIGMAR1MC4RMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0751937-A1 | N-(BENZHYDRYLOXYALKYL)-4-(CARBOXY/CARBAMOYL-METHYL)-PIPERIDINE DERIVATIVES AS ANTIDEPRESSANTS | COOPERATION PHARMACEUTIQUE FRANCAISE (FR) | 1997-01-08 | — | — | EP | claimed |
| WO-1995026336-A1 | N-(BENZHYDRYLOXYALKYL)-4-(CARBOXY/CARBAMOYL-METHYL)-PIPERIDINE DERIVATIVES AS ANTIDEPRESSANTS | COOPERATION PHARMACEUTIQUE FRANCAISE (FR) | 1995-10-05 | — | — | WO | claimed |
| US-11999734-B2 | Compounds and compositions for the treatment of cystic fibrosis | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2024-06-04 | — | — | US | disclosed |
| EP-3820867-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | FONDAZIONE ST ITALIANO TECNOLOGIA (IT) | 2023-09-13 | — | — | EP | disclosed |
| US-20210292324-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | ISTITUTO GIANNINA GASLINI (IT) | 2021-09-23 | — | — | US | disclosed |
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2019-07-02 | — | — | US | disclosed |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | MEDSHINE DISCOVERY INC. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | MEDSHINE DISCOVERY INC. (CN) | 2019-03-12 | — | — | US | disclosed |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-07-05 | — | — | US | disclosed |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-07-05 | — | — | US | disclosed |
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | MEDSHINE DISCOVERY INC. (CN) | 2018-06-14 | — | — | US | disclosed |
| WO-2001046181-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | ELI LILLY AND COMPANY (US) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001023381-A1 | PIPERIDINE DERIVATIVES AS REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001023380-A1 | PIPERIDINE DERIVATIVES AS SEROTONINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-04-05 | — | — | WO | disclosed |
| WO-2001000577-A2 | PREPARATION OF SUBSTITUTED PIPERIDIN-4-ONES | ELI LILLY AND COMPANY (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0982304-A1 | Piperidine derivatives having effects on serotonin related systems | ELI LILLY AND COMPANY (US) | 2000-03-01 | — | — | EP | disclosed |
| WO-2000000198-A1 | PIPERIDINE DERIVATIVES HAVING EFFECTS ON SEROTONIN RELATED SYSTEMS | ELI LILLY AND COMPANY (US) | 2000-01-06 | — | — | WO | disclosed |
| US-5846980-A | N-(benzhydryloxyalkyl)-4-(carboxy/carbamoyl methyl)-piperidine derivatives as antidepressants | COOPERATION PHARMACEUTIQUE FRANCAISE (FR) | 1998-12-08 | — | — | US | disclosed |
| EP-0751937-A1 | N-(BENZHYDRYLOXYALKYL)-4-(CARBOXY/CARBAMOYL-METHYL)-PIPERIDINE DERIVATIVES AS ANTIDEPRESSANTS | COOPERATION PHARMACEUTIQUE FRANCAISE (FR) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995026336-A1 | N-(BENZHYDRYLOXYALKYL)-4-(CARBOXY/CARBAMOYL-METHYL)-PIPERIDINE DERIVATIVES AS ANTIDEPRESSANTS | COOPERATION PHARMACEUTIQUE FRANCAISE (FR) | 1995-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162878-A1 | ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE | NDUFV1, NDUFV2, MT-ND4 | GAA 994/4885NR3C1 1061/4885SIGMAR1 2611/4885 |
| US-11999734-B2 | Compounds and compositions for the treatment of cystic fibrosis | CFTR, ABCB11, ABCC5 | GAA 660/4885NR3C1 3441/4885SIGMAR1 1714/4885 |
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | GAA 3727/4885NR3C1 34/4885SIGMAR1 2751/4885 |
| US-20210292324-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, ABCB11, ABCC5 | GAA 660/4885NR3C1 3441/4885SIGMAR1 1714/4885 |
| US-10227362-B2 | Anti-pulmonary tuberculosis nitroimidazole derivative | NDUFV1, NDUFV2, MT-ND4 | GAA 994/4885NR3C1 1061/4885SIGMAR1 2611/4885 |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | GAA 3821/4885NR3C1 34/4885SIGMAR1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.